Heterocyclic Scaffolds as Therapeutic Agents in Multiple Sclerosis: Mechanisms and SAR Study

Multiple sclerosis (MS) is a progressive, immune-mediated condition characterized by the destruction of myelin, the protective insulation surrounding nerve fibers. This ongoing assault triggers a cascade of damage, including persistent inflammatory responses, loss of myelinproducing oligodendrocytes, axonal degradation, and cumulative neurological impairment. While motor and sensory difficulties are hallmark features, patients frequently contend with less visible but equally debilitating symptoms such as cognitive dysfunction, profound fatigue, affective disorders, nerve pain, and autonomic instability. These often-overlooked manifestations critically impact well-being and functional capacity. The pathophysiology of MS is increasingly understood as a network of overlapping cellular and molecular dysfunctions. Alongside irregularities in the endocannabinoid signaling network, key contributors include aberrant immune communication, persistently activated microglia, impaired mitochondrial energy production, and dysregulated activity of enzymes like PDE7, MAGL, ROCK, and PADs. These interconnected pathways collectively drive disease initiation and advancement. This analysis synthesizes established information on current FDA-approved treatments for MS and examines promising novel small-molecule compounds aimed at specific disease-relevant targets. A significant focus is placed on medicinal chemistry advancements, particularly the design and optimization of heterocyclic compounds. Scaffolds incorporating quinolines, pyrimidines, indoles, and related nitrogen-containing structures demonstrate considerable potential for conferring immunomodulation, reducing inflammation, and protecting neural tissue. By evaluating structure-activity relationships, binding mechanisms, and strategic drug design, this review offers an integrated perspective to inform the creation of new, targeted therapies for MS.